The purpose of these rules is to provide administrative details and procedures for the care and treatment of newborns identified with phenylketonuria, hypothyroidism, galactosemia, congenital adrenal hyperplasia, hearing loss, hemoglobinopathy, biotinidase deficiency, cystic fibrosis, aminoacidopathies, fatty acid oxidation disorders, organic acidurias and acidemias, critical congenital heart disease, severe combined immunodeficiency, spinal muscular atrophy, x-1inked adrenoleukodystrophy, lysosomal storage disorders, and other heritable diseases.

Author: P. Scott Harris, M.D., Thomas M. Miller, M.D., Lucinda G. Ashley, R.N. – B.C., Rachael N. Montgomery, B.S.N., R.N.

Statutory Authority: Code of Ala. 1975, §§22-2-2, 22-20-3.

History: Filed December 21, 1987. Amended: Filed September 18, 2002; effective October 23, 2002. Repealed and New Rule: Filed December 17, 2003; effective January 21, 2004. Amended: Filed December 17, 2007; effective January 21, 2008. Amended: Filed May 17, 2013; effective June 21, 2013. Amended: Filed January 19, 2017; effective March 5, 2017. Amended: Published December 30, 2021; effective February 13, 2022.